Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 667)


One of the major advances in the treatment of cancer with lipid A is the possibility of chemically synthesizing, lipid A analogs that are both biologically active in cancer patients and very well tolerated. Biotechnological production of different lipid A forms is also possible but the chemical route is preferable as it avoids LPS contamination. This significant step was somewhat unexpected as in the 1980s the debate had centered on the question “Is it possible to separate the toxic activity of lipid A from its anti-tumor activity?” and I will come back to this question here.


Antitumor Activity Innate Immune Cell Kill Tumor Cell Specific Immune Response Biotechnological Production 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Miller SI, Ernst RK, and Bader MW. LPS, TLR4 and infectious disease diversity. Nat Rev Microbiol 2005; 3:36–46.CrossRefPubMedGoogle Scholar
  2. 2.
    Tsuji S, Matsumoto M, Takeuchi O et al. Maturation of human dendritic cells by cell wall skeleton of Mycobacterium bovis bacillus Calmette-Guerin: involvement of toll-like receptors. Infect Immun 2000; 68:6883–6890.CrossRefPubMedGoogle Scholar
  3. 3.
    Okamoto M, Oshikawa T, Tano T et al. Involvement of Toll-like receptor 4 signaling in interferon-gamma production and antitumor effect by streptococcal agent OK-432. J Natl Cancer Inst 2003; 95:316–326.CrossRefPubMedGoogle Scholar
  4. 4.
    Whitmore MM, DeVeer MJ, Edling A et al. Synergistic activation of innate immunity by double-stranded RNA and CpG DNA promotes enhanced antitumor activity. Cancer Res 2004; 64:5850–5860.CrossRefPubMedGoogle Scholar
  5. 5.
    Jahrsdorfer B, Muhlenhoff L, Blackwell SE et al. B-celllymphomas differ in their responsiveness to CpG oligodeoxynucleotides. Clin Cancer Res 2005; 11:1490–1499.CrossRefPubMedGoogle Scholar

Copyright information

© Landes Bioscience and Springer Science+Business Media 2009

Authors and Affiliations

  1. 1.Tumor Immunology and Immunotherapy Laboratory Inserm U866University of BurgundyDijonFrance

Personalised recommendations